X
DNA icon

Xponance’s Ginkgo Bioworks DNA Stock Holding History

Xponance’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,913
Closed -$88.8K – 1331
2024
Q1 		$88.8K Buy
1,913
+186
+11% +$9.63K ﹤0.01% 1247
2023
Q4 		$117K Sell
1,727
-17
-1% -$1.04K ﹤0.01% 1199
2023
Q3 		$126K Buy
1,744
+30
+2% +$2.4K ﹤0.01% 1151
2023
Q2 		$127K Buy
1,714
+607
+55% +$35.9K ﹤0.01% 1181
2023
Q1 		$58.9K Sell
1,107
-152
-12% -$9.63K ﹤0.01% 1184
2022
Q4 		$85.1K Buy
1,259
+411
+48% +$37.8K ﹤0.01% 1159
2022
Q3 		$106K Buy
848
+12
+1% +$1.43K ﹤0.01% 1113
2022
Q2 		$80K Buy
+836
New +$102K ﹤0.01% 1134

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Xponance's DNA Position: Q2 2024 in Review

Xponance sold out of Ginkgo Bioworks (DNA) in Q2 2024, closing a stake of 1,913 shares — an estimated $88.8K sold.

Xponance first reported a position in DNA in Q2 2022 and held it in 8 quarters. The position peaked at $127K in Q2 2023. 313 funds tracked by Wall St. Rank hold DNA as of Q2 2024.

  • Xponance reported no remaining Ginkgo Bioworks position as of Q2 2024 after selling out during the quarter.
  • Xponance sold 1,913 Ginkgo Bioworks shares in Q2 2024, an estimated $88.8K.
  • Xponance first reported a position in Ginkgo Bioworks in Q2 2022 and held it in 8 quarters.
  • Xponance's Ginkgo Bioworks position peaked at $127K in Q2 2023.
  • 313 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2024.

Based on Xponance's 13F filing for Q2 2024, filed 14 Aug 2024.